To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Improved Patient Profiling with Randox Metabolic Syndrome Arrays
Read time: Less than a minute
The Metabolic Syndrome Arrays from Randox offer simultaneous determination of analytes associated with Metabolic Syndrome and related disorders for improved patient profiling.
Metabolic Syndrome is a clustering of cardiovascular risk factors. Individuals with Metabolic Syndrome are three times more likely to have a stroke or heart attack and five times more likely to develop type 2 diabetes, this highlights the seriousness of the syndrome. The IDF Metabolic Syndrome worldwide definition states that an individual must have central obesity plus at least two of the following four factors; raised triglycerides, reduced HDL cholesterol, raised blood pressure and raised fasting plasma glucose.
Metabolic Syndrome Array I includes these analytes; C-peptide, Ferritin, IL-1a, IL-6, Insulin, Leptin, Plasminogen Activator Inhibitor-I, Resistin and Tumour Necrosis Factor a. Metabolic Syndrome Array II includes; Adiponectin, CRP and Cystatin C. Utilizing proven multiplexing Biochip technology, these arrays provide cost and time savings as multiple assays can be run on one sample.
The Metabolic Syndrome Arrays are suitable for use on plasma and serum, using only 100 µl of sample to measure all analytes on each array. Randox also offer a complete range of multi-analyte controls and calibrators to ensure reliable results.
Metabolic Syndrome is a clustering of cardiovascular risk factors. Individuals with Metabolic Syndrome are three times more likely to have a stroke or heart attack and five times more likely to develop type 2 diabetes, this highlights the seriousness of the syndrome. The IDF Metabolic Syndrome worldwide definition states that an individual must have central obesity plus at least two of the following four factors; raised triglycerides, reduced HDL cholesterol, raised blood pressure and raised fasting plasma glucose.
Metabolic Syndrome Array I includes these analytes; C-peptide, Ferritin, IL-1a, IL-6, Insulin, Leptin, Plasminogen Activator Inhibitor-I, Resistin and Tumour Necrosis Factor a. Metabolic Syndrome Array II includes; Adiponectin, CRP and Cystatin C. Utilizing proven multiplexing Biochip technology, these arrays provide cost and time savings as multiple assays can be run on one sample.
The Metabolic Syndrome Arrays are suitable for use on plasma and serum, using only 100 µl of sample to measure all analytes on each array. Randox also offer a complete range of multi-analyte controls and calibrators to ensure reliable results.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
